866-997-4948(US-Canada Toll Free)

EpiCast Report: Chronic Kidney Disease-Epidemiology Forecast to 2026

Published By :

GlobalData

Published Date : Dec 2017

Category :

Pharmaceutical

No. of Pages : 32 Pages

EpiCast Report: Chronic Kidney Disease - Epidemiology Forecast to 2026

Summary

Chronic kidney disease (CKD), or chronic renal disease, is an asymptomatic, long-term condition that damages the kidneys and leads to the loss of kidney function over time (NIH, 2010). As the disease progresses, the symptoms worsen, eventually leading to kidney failure (NIH, 2010). The glomerular filtration rate (GFR), a key measure of kidney function, is determined by the amount of creatinine in the blood, and the Kidney Disease, Improving Global Outcomes (KDIGO) classification system is considered the standard for GFR measurement and diagnosis of CKD.

GlobalData epidemiologists provide a 10-year epidemiological forecast for the total prevalent cases (including both diagnosed and undiagnosed cases) of CKD Stages I-IV by age and sex, the total prevalent cases of CKD by stage, the diagnosed prevalent cases of CKD Stages I-V, and the diagnosed prevalent cases of CKD by stage.

In the 7MM, GlobalData epidemiologists forecast the diagnosed prevalent cases of CKD, Stages I-V, to increase from 25,775,828 cases in 2016 to 28,325,839 cases in 2026, at an Annual Growth Rate (AGR) of 0.99%. The UK will have the highest number of diagnosed cases of CKD throughout the forecast period.

Scope

- The Chronic Kidney Disease EpiCast Report provides an overview of the risk factors and global trends of chronic kidney disease in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- This report also includes a 10-year epidemiological forecast for the total prevalent cases of CKD, Stages I-IV, segmented by age (beginning at 20 years and ending at ages 80 years and older), by sex, and by stage. Furthermore, this report includes a forecast of the diagnosed prevalent cases of CKD, Stages I-V, and the diagnosed prevalent cases of CKD by stage.
- The chronic kidney disease epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Chronic Kidney Disease EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global chronic kidney disease treatment market.
- Quantify patient populations in the chronic kidney disease market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for chronic kidney disease therapeutics in each of the markets covered.
- Understand magnitude of chronic kidney disease.
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Chronic Kidney Disease: Executive Summary 4
2.1 Related Reports 5
2.2 Upcoming Reports 6
3 Epidemiology 7
3.1 Disease Background 7
3.2 Risk Factors and Comorbidities 8
3.3 Global and Historical Trends 8
3.4 Forecast Methodology 9
3.4.1 Sources 10
3.4.2 Forecast Assumptions and Methods 14
3.5 Epidemiological Forecast for CKD (2016-2026) 20
3.5.1 Total Prevalent Cases of CKD, Stages I-IV 20
3.5.2 Age-Specific Total Prevalent Cases of CKD, Stages I-IV 20
3.5.3 Sex-Specific Total Prevalent Cases of CKD, Stages I-IV 21
3.5.4 Total Prevalent Cases of CKD by Stage 22
3.5.5 Diagnosed Prevalent Cases of CKD, Stages I-V 23
3.5.6 Diagnosed Prevalent Cases of CKD by Stage 24
3.6 Discussion 25
3.6.1 Epidemiological Forecast Insight 25
3.6.2 Limitations of the Analysis 26
3.6.3 Strengths of the Analysis 26
4 Appendix 27
4.1 Bibliography 27
4.2 About the Authors 29
4.2.1 Epidemiologists 29
4.2.2 Reviewers 29
4.2.3 Global Director of Therapy Analysis and Epidemiology 30
4.2.4 Global Head and EVP of Healthcare Operations and Strategy 31
4.3 About GlobalData 32
4.4 Contact Us 32
4.5 Disclaimer 32

1.1 List of Tables
Table 1: KDIGO Classification of CKD 7
Table 2: Risk Factors and Comorbidities for CKD 8
Table 3: 7MM, Total Prevalent Cases of CKD, Stages I-IV, Both Sexes, Ages 20 Years, N, Selected Years from 2016-2026 20
Table 4: 7MM, Diagnosed Prevalent Cases of CKD, Stages I-V, Both Sexes, Ages 20 Years, N, Selected Years from 2016-2026 24

1.2 List of Figures
Figure 1: 7MM, Diagnosed Prevalent Cases of CKD, Stages I-V, Both Sexes, Ages 20 Years, N, 2016 and 2026 5
Figure 2: 7MM, Age-Standardized Total Prevalence of CKD, Stages I-IV, Ages 20 Years, 2016 9
Figure 3: 7MM, Sources Used to Forecast the Total Prevalent Cases of CKD Stages I-IV 10
Figure 4: 7MM, Sources Used to Forecast the Total Prevalent Cases of CKD by Stage 11
Figure 5: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of CKD Stages I-IV 12
Figure 6: 7MM, Sources Used to Forecast the Number of CKD Cases on Dialysis 13
Figure 7: 7MM, Sources Used to Forecast the Number of New Kidney Transplants 14
Figure 8: 7MM, Age-Specific Total Prevalent Cases of CKD, Stages I-IV, Both Sexes, Ages 20 Years, N, 2016 21
Figure 9: 7MM, Sex-Specific Total Prevalent Cases of CKD, Stages I-IV, Both Sexes, Ages 20 Years, N, 2016 22
Figure 10: 7MM, Total Prevalent Cases of CKD by Stage, Both Sexes, Ages 20 Years, N, 2016 23
Figure 11: 7MM, Diagnosed Prevalent Cases of CKD by Stage, Both Sexes, Ages 20 Years, N, 2016 25

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *